These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 8640297)

  • 21. Dopamine resistance of prolactinomas.
    Molitch ME
    Pituitary; 2003; 6(1):19-27. PubMed ID: 14674720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactinoma presenting as painful postganglionic Horner syndrome.
    Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
    Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
    [No Abstract]   [Full Text] [Related]  

  • 23. The cabergoline-resistant prolactinoma patient: new challenges.
    Molitch ME
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of macroprolactinoma with cabergoline during pregnancy].
    Forsbach-Sánchez G; Tamez-Pérez HE; Hernández-Herrera R; Bafidis-Lechuga B
    Rev Med Inst Mex Seguro Soc; 2009; 47(3):307-10. PubMed ID: 20141661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Colao A; Lombardi G
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
    Biswas M; Smith J; Jadon D; McEwan P; Rees DA; Evans LM; Scanlon MF; Davies JS
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):26-31. PubMed ID: 15963057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
    Lebbe M; Hubinont C; Bernard P; Maiter D
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prolactinoma and pregnancy].
    Trifonov I
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
    [No Abstract]   [Full Text] [Related]  

  • 30. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
    Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
    Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
    Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
    Mohan N; Chia YY; Goh GH; Ting E; Teo K; Yeo TT
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29102970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.
    Balarini Lima GA; Machado Ede O; Dos Santos Silva CM; Filho PN; Gadelha MR
    Pituitary; 2008; 11(3):287-92. PubMed ID: 17570067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of cabergoline in the treatment of macroprolactinoma].
    Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
    Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
    [No Abstract]   [Full Text] [Related]  

  • 35. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
    Oguz A; Tuzun D; Sahin M; Gul K
    Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic resistance in prolactinoma patients.
    Molitch ME
    Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
    Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
    Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.
    Behan LA; Draman MS; Moran C; King T; Crowley RK; O'Sullivan EP; Smith D; Thompson CJ; Agha A
    Pituitary; 2011 Dec; 14(4):362-6. PubMed ID: 19191028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E; Crabbé J; Donckier J
    Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.